A Phase 3 interventional study of Lebrikizumab and Placebo in Dermatitis, Atopic, Dermatitis and Eczema, sponsored by Eli Lilly and Company. Completed at 37 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-08-23.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is one of 17 in phase 3, and was the 10th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
Forefront Dermatology S.C · Sites in United States
Ages 12+
Almirall, S.A.
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 286 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 252 across the 24 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
30 studies in Dermatitis, Atopic by Eli Lilly and Company: 1 open now, 2 under way, 2 of them phase 3. Of 28 finished, 25 (89%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 15th largest by enrollment, is the only one that started in 2021, is one of 21 in phase 3, and was the 20th registered.
Eli Lilly and Company’s Dermatitis, Atopic studies by the year they started, since 2013.
3 of the studies testing lebrikizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
| NCT07856134Forefront Dermatology S.CAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, from their registry updates:
Among Eli Lilly and Company’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have moderate-to-severe AD, including all of the following:
Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 500 mg of Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections as a loading dose at Baseline followed by 250 mg of Lebrikizumab administered SC Q4W from Week 4 until Week 12, in combination with topical corticosteroid. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
Drug: Lebrikizumab · Drug: Topical Corticosteroid
Participants received 500 mg of Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 followed by 250 mg of Lebrikizumab administered SC Q2W from Week 4 until Week 14, in combination with topical corticosteroid. Week 16 responders entered maintenance period and were randomly allocated to receive 250 mg lebrikizumab Q2W or 250 mg lebrikizumab Q4W, in a 1:1 ratio. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
Drug: Lebrikizumab · Drug: Topical Corticosteroid
Participants received two SC injections of Placebo as a loading dose at Baseline in combination with topical corticosteroid and Week 2 followed by a single injection Q2W from Week 4 until Week 14. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
Drug: Placebo · Drug: Topical Corticosteroid
Administered SC
Also known as: LY3650150
Administered SC
Self-applied
Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Time frame: Baseline to Week 16
Percentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75) (≥75% Reduction in EASI Score) at Week 16
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.
Time frame: Week 16
Percent Change in Eczema Area Severity Index (EASI) Score From Baseline to Week 16
The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Square (LS) Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.
Time frame: Baseline to Week 16
Percentage of Participants Achieving EASI-90 at Week 16
The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.
Time frame: Week 16
Percentage of Participants With an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 1
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 1
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 2
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 2
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 4
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 4
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 16
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 16
Induction period (16-weeks): Participants were randomly assigned to 250mg Lebrikizumab every 2 weeks (Q2W) or 250mg Lebrikizumab every 4 weeks (Q4W) or Placebo. Maintenance period (52-weeks): At week 16, responders from 250mg Lebrikizumab Q2W were re-randomised to 250mg Lebrikizumab Q2W and 250mg Lebrikizumab Q4W; responders from 250mg Lebrikizumab Q4W or Placebo arms continued with same treatment. Responders were defined as having an IGA of 0 or 1 or a 75% reduction in EASI (EASI-75).
| Milestone | Induction - Placebo | Induction - Lebrikizumab 250mg Q4W | Induction - Lebrikizumab 250mg Q2W | Maintenance Blinded Period - Placebo Responder/Placebo | Maintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2W | Escape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 82 | 81 | 123 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 82 | 81 | 123 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 82 | 80 | 120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction - Placebo | Induction - Lebrikizumab 250mg Q4W | Induction - Lebrikizumab 250mg Q2W | Maintenance Blinded Period - Placebo Responder/Placebo | Maintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2W | Escape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 11 | 38 | 33 | 32 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 0 | 0 | 0 | 11 | 38 | 33 | 32 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 9 | 35 | 27 | 27 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 3 | 6 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled to escape arm | 0 | 0 | 0 | 1 | 0 | 4 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Assigned treatment by mistake | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction - Placebo | Induction - Lebrikizumab 250mg Q4W | Induction - Lebrikizumab 250mg Q2W | Maintenance Blinded Period - Placebo Responder/Placebo | Maintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2W | Escape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 42 | 55 | 8 |
| Received at least one dose of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 42 | 55 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63 | 40 | 48 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 7 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 5 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
| Percentage of participants | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 | 6.1 (0.9 to 11.3) | 29.1 (19.2 to 39.1) | 33.4 (25.0 to 41.8) |
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.
| Percentage of participants | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75) (≥75% Reduction in EASI Score) at Week 16 | 13.4 (6.0 to 20.8) | 47.2 (36.3 to 58.1) | 51.2 (42.3 to 60.1) |
The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Square (LS) Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.
| Percent change | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percent Change in Eczema Area Severity Index (EASI) Score From Baseline to Week 16 | -25.25 ± 4.765 | -59.74 ± 4.920 | -64.23 ± 4.402 |
The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.
| Percentage of participants | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving EASI-90 at Week 16 | 9.8 (3.3 to 16.2) | 28.4 (18.6 to 38.3) | 34.3 (25.9 to 42.7) |
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| Percentage of participants | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percentage of Participants With an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 1 | 0 (0 to 0) | 0 (0 to 0) | 1.3 (0.0 to 3.7) |
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| Percentage of participants | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 2 | 0 (0.0 to 0.0) | 1.7 (0.0 to 5.0) | 3.8 (0.0 to 7.9) |
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| Percentage of participants | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 4 | 0 (0.0 to 0.0) | 8.5 (1.4 to 15.6) | 16.3 (8.2 to 24.3) |
The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| Percentage of participants | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W |
|---|---|---|---|
| Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 16 | 3.3 (0.0 to 7.9) | 23.8 (12.9 to 34.7) | 32.7 (22.4 to 43.0) |
Collected over Baseline Up To Week 68.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction - Placebo | 0/82 (0%) | 2/82 (2.4%) | 52/82 (63.4%) |
| Induction - Lebrikizumab 250mg Q4W | 0/81 (0%) | 0/81 (0%) | 49/81 (60.5%) |
| Induction - Lebrikizumab 250mg Q2W | 0/123 (0%) | 1/123 (0.8%) | 93/123 (75.6%) |
| Maintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4W | 0/38 (0%) | 1/38 (2.6%) | 31/38 (81.6%) |
| Maintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4W | 0/33 (0%) | 0/33 (0%) | 25/33 (75.8%) |
| Maintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2W | 0/32 (0%) | 1/32 (3.1%) | 29/32 (90.6%) |
| Maintenance Blinded Period - Placebo Responder/Placebo | 0/11 (0%) | 0/11 (0%) | 10/11 (90.9%) |
| Escape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2W | 0/71 (0%) | 1/71 (1.4%) | 63/71 (88.7%) |
| Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2W | 0/42 (0%) | 2/42 (4.8%) | 36/42 (85.7%) |
| Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2W | 0/55 (0%) | 1/55 (1.8%) | 49/55 (89.1%) |
| Escape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| Event | Induction - Placebo | Induction - Lebrikizumab 250mg Q4W | Induction - Lebrikizumab 250mg Q2W | Maintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2W | Maintenance Blinded Period - Placebo Responder/Placebo | Escape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/82 | 0/81 | 0/123 | 0/38 | 0/33 | 0/32 | 0/11 | 0/71 | 0/42 | 0/55 | 1/8 |
| Ligament injuryInjury, poisoning and procedural complications | 0/82 | 0/81 | 0/123 | 0/38 | 0/33 | 1/32 | 0/11 | 0/71 | 0/42 | 0/55 | 0/8 |
| Anaphylactic reactionImmune system disorders | 0/82 | 0/81 | 0/123 | 1/38 | 0/33 | 0/32 | 0/11 | 0/71 | 0/42 | 0/55 | 0/8 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/82 | 0/81 | 0/123 | 0/38 | 0/33 | 0/32 | 0/11 | 0/71 | 1/42 | 0/55 | 0/8 |
| Tooth extractionSurgical and medical procedures | 0/82 | 0/81 | 0/123 | 0/38 | 0/33 | 0/32 | 0/11 | 0/71 | 1/42 | 0/55 | 0/8 |
| TonsillitisInfections and infestations | 0/82 | 0/81 | 0/123 | 0/38 | 0/33 | 0/32 | 0/11 | 0/71 | 0/42 | 1/55 | 0/8 |
| Covid-19Infections and infestations | 1/82 | 0/81 | 0/123 | 0/38 | 0/33 | 0/32 | 0/11 | 1/71 | 0/42 | 0/55 | 0/8 |
| Campylobacter gastroenteritisInfections and infestations | 1/82 | 0/81 | 0/123 | 0/38 | 0/33 | 0/32 | 0/11 | 0/71 | 0/42 | 0/55 | 0/8 |
| Cerebral infarctionNervous system disorders | 0/82 | 0/81 | 1/123 | 0/38 | 0/33 | 0/32 | 0/11 | 0/71 | 0/42 | 0/55 | 0/8 |
| Back painMusculoskeletal and connective tissue disorders | 0/82 | 0/81 | 0/123 | 0/38 | 0/33 | 0/32 | 0/11 | 0/71 | 0/42 | 0/55 | 0/8 |
| Event | Induction - Placebo | Induction - Lebrikizumab 250mg Q4W | Induction - Lebrikizumab 250mg Q2W | Maintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4W | Maintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2W | Maintenance Blinded Period - Placebo Responder/Placebo | Escape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2W | Escape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 13/82 | 15/81 | 25/123 | 7/38 | 6/33 | 11/32 | 3/11 | 13/71 | 4/42 | 5/55 | 0/8 |
| Covid-19Infections and infestations | 2/82 | 2/81 | 1/123 | 7/38 | 7/33 | 4/32 | 0/11 | 13/71 | 8/42 | 12/55 | 2/8 |
| Herpes simplexInfections and infestations | 2/82 | 1/81 | 1/123 | 3/38 | 3/33 | 1/32 | 0/11 | 2/71 | 8/42 | 2/55 | 0/8 |
| Conjunctivitis allergicEye disorders | 4/82 | 10/81 | 21/123 | 5/38 | 1/33 | 4/32 | 0/11 | 13/71 | 1/42 | 3/55 | 0/8 |
| Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/82 | 1/81 | 3/123 | 2/38 | 1/33 | 1/32 | 2/11 | 3/71 | 4/42 | 1/55 | 0/8 |
| HeadacheNervous system disorders | 9/82 | 3/81 | 4/123 | 1/38 | 6/33 | 4/32 | 1/11 | 4/71 | 2/42 | 2/55 | 1/8 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/82 | 1/81 | 1/123 | 0/38 | 1/33 | 0/32 | 2/11 | 1/71 | 0/42 | 0/55 | 0/8 |
| AcneSkin and subcutaneous tissue disorders | 5/82 | 2/81 | 4/123 | 1/38 | 6/33 | 3/32 | 1/11 | 5/71 | 3/42 | 6/55 | 1/8 |
| DysmenorrhoeaReproductive system and breast disorders | 0/24 | 0/25 | 2/41 | 0/15 | 2/12 | 1/12 | 0/5 | 2/19 | 0/9 | 1/15 | 0/3 |
| NasopharyngitisInfections and infestations | 2/82 | 5/81 | 7/123 | 2/38 | 2/33 | 3/32 | 1/11 | 8/71 | 6/42 | 7/55 | 1/8 |
All randomized participants.
| Age, Continuous(years) | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 34.80 ± 13.60 | 37.80 ± 12.02 | 35.50 ± 12.24 | 36.00 ± 12.59 |
| Sex: Female, Male(Participants) | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W | Total |
|---|---|---|---|---|
| Female | 24 | 25 | 41 | 90 |
| Male | 58 | 56 | 82 | 196 |
| Ethnicity (NIH/OMB)(Participants) | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 82 | 81 | 123 | 286 |
| Race (NIH/OMB)(Participants) | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 82 | 81 | 123 | 286 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Induction - Placebo | Induction - Lebrikizumab 250 mg Q4W | Induction - Lebrikizumab 250 mg Q2W | Total |
|---|---|---|---|---|
| Japan | 82 | 81 | 123 | 286 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2021 to primary completion in Jul 2022, 16 months.
Results were first posted in Aug 2023, 1 year after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 16 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab